Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=33440 A friend of mine, Shahram Mori, recently pointed to this issue -- as a way to play trickle down from recent sector liquidity. Current market cap is $43 million. Tuesday February 15, 9:22 am Eastern Time Company Press Release SOURCE: DGI BioTechnologies, LLC. DGI BioTechnologies, LLC., Makes Key Additions to Scientific Team EDISON, N.J., Feb. 15 /PRNewswire/ -- DGI BioTechnologies, LLC. (DGI), which is majority owned by New Brunswick Scientific Co., Inc. (Nasdaq: NBSC - news), today announced that it has made the following key additions to its core scientific team: Director of Protein Technologies-Michael Lennick, Ph.D. Director of Molecular Biology-Neil I. Goldstein, Ph.D. Group Leader of High-Throughput Screening (HTS)-Paul W. Fletcher, Ph.D. Dr. Lennick, 47, is a protein biochemist with over 20 years' experience in research and development, specializing in monoclonal antibodies, vaccines, recombinant proteins and human blood products, complemented by a background in immunochemistry and assay development. Most recently, he was Assistant Director in Charge of Pharmaceutical Processing for Medarex Corporation in Clinton, New Jersey. Dr. Lennick earned his Ph.D. in Biology from Wesleyan University in 1982 and was a postdoctoral fellow with the American Red Cross in Bethesda, Maryland, from 1982 to 1984. Dr. Goldstein, 51, well versed in all aspects of immunology, molecular biology, biochemistry, and cell biology, joined DGI from GenQuest, Inc., New York, New York, where he was Vice President and Director of Molecular and Cell Biology. Dr. Goldstein received his Ph.D. in Microbiology from Rutgers University in 1975 and was a postdoctoral fellow, The Waksman Institute of Microbiology at Rutgers University (1975-76); and The Wistar Institute (1976- 78). Dr. Fletcher, 48, is a biochemical pharmacologist with over 20 years of experience in research and development, specializing in receptor biochemistry, signal transduction and assay development. Before joining DGI, he served as Manager of Pharmacology and as a Program Manager in Wound Healing for ProCyte Corporation in Redmond, Washington. Dr. Fletcher attended the University of Wyoming (1975-78) where he received his Ph.D. in Biochemistry and Reproductive Physiology, and was an NIH postdoctoral fellow, Biochemical Endocrinology, (1978-80) at Colorado State University. DGI President and Chief Executive Officer Dr. Arthur J. Blume said: ''With DGI poised to become an integral part of future drug discoveries, one of our many objectives is the establishment of a comprehensive infrastructure to support strategic growth.'' He continued, ''Dr. Lennick's expertise gives DGI the ability to obtain sufficient, often difficult-to-make quantities of drug targets needed for HTS. Dr. Goldstein brings master skills with nucleic acids required for the generation and use of our surrogate libraries. These libraries are utilized in target validation and selection and providing the surrogates n...https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=3344038013210